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Abstract 
Reactions of 2-bromo-6-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (L1), 2,6-di (1H-
pyrazol-1-yl) pyridine (L2) and 2,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (L3) with 
RuCl3·3H2O led to the formation of their respective metal complexes [RuCl3(L1)] (1), 
[RuCl3(L2)] (2) and [RuCl3(L3)] (3). Solid state structure of complex 3 established the 
formation of a six-coordinate mononuclear compound in which L3 is tridentately bound. The 
order of reactivity of the studied complexes with thiourea (TU) nucleophile is in the form 1 > 
2 > 3, in line with density functional theory (DFT) studies. The complexes displayed minimal 
cytotoxic activity against the HeLa cell line, consistent with molecular docking experiments 
which showed weaker DNA binding affinities. 
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Cancer is the second leading cause of death globally, only surpassed by cardiovascular 
diseases, with nearly 1 in 6 deaths due to cancer [1]. Following the discovery of the platinum-
based drug cisplatin for treating cancer, a wide spectrum of platinum(II)-based complexes have 
been developed and are commercially available, e.g.,  carboplatin [2]. However, there are 
currently limitations to the clinical use of cisplatin and its analogues, e.g., dose-limiting toxicity 
and resistance [3].  Thus, there has been a surge in the development of alternative drugs without 
the demerits of platinum-based analogues. Notable examples include the ruthenium(II)  
compounds which have shown some promising results [4]. However, a key challenge in the 
development of metal-based drugs lies in understanding the drug-host interactions, in addition 
to the intrinsic properties of the complexes. Therefore, to have a better understanding of the 
mechanisms and mode of action of metallo-drugs, a combination of experimental and 
theoretical platforms is critical and is currently being explored. These include studying the 
kinetics of substitution reactions [5] with biologically relevant molecules, molecular docking 
[6] and DNA binding studies [7].  
As an illustration, Bratsos et al. established that anticancer activities of ruthenium(II) 
half sandwich complexes are directly related to the rate of hydrolysis of the complexes [8]. In 
a more recent study, the anti-cancer activities of two ruthenium(II) complexes, [Ru(Cl-
tpy)(en)Cl][Cl] and Ru(Cl-tpy)(dach)Cl][Cl] reveal that the lower rate of substitution of the 
coordinated chloride ligand with biologically relevant L-His in comparison to 5′-GMP is 
responsible for their anti-tumor activity due limited cytoplasmic deactivation [9].   An example 
where DNA binding and molecular docking has been used to interrogate the cytotoxicity of 
metal compounds is well presented in the recent report of Hong et al. [10] using enantiomeric 
ruthenium(II) complexes. A positive correlation between the binding affinities of the 
compounds to the DNA and their anti-cancer activities was observed. In this communication, 
we report the application of a combination of kinetics of ligand substitution reactions, 
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molecular docking and theoretical studies to investigate the anti-cancer activities of 
(pyrazolyl)pyridine ruthenium(III) compounds.  
The compounds, 2-bromo-6-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (L1), 2,6-di (1H-
pyrazol-1-yl) pyridine (L2) and 2,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (L3)  ligands 
were synthesised following  literature methods [11]. Reactions of L1-L3 with RuCl3·3H2O 
resulted in the formation of the corresponding ruthenium(III) metal complexes 1-3 in good 
yields (Scheme 1). Mass spectrometry, elemental analyses and single crystal X-ray analyses 
was used to characterize the complexes. For example, the ESI-MS mass spectrum of complex 
3 (Figure S1) showed a base peak at 439.01 amu, corresponding to the [Ru(L3)Cl2]
+ fragment. 
The elemental analyses data of complexes 1–3 were in good agreement with one metal centre 
and one ligand motif as proposed in Scheme 1. While penta-coordinated Ru(III) complexes are 
rare, both the elemental analyses and MS (m/z = 424.85: M+ - Cl) data collected for complex 
1 agree with the proposed structure. However, it is possible that the crystal structure of 1 may 
contain a solvent molecule in the sixth coordination sphere as we previously reported for 
similar Ru(III) complexes [12].   
 
 
Scheme 1: Syntheses of (pyrazolyl)pyridine ruthenium(III) complexes 1-3. 
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The molecular structure of complex 3 is shown in Figure 1, while Table S1 contains 
crystallographic data and structure refinement parameters. The coordination around the metal 
atom consists of one tridentate ligand L3 and three chloride ligands to give a six-coordination 
environment. The bond angles for instance N(5)-Ru(1)-Cl(1) of 91.82° deviate from 90°, 
consistent with a distorted octahedral geometry. The shorter bond distances for Ru-Cl(1)  and 
Ru-Cl(2)  of 2.3540(5) and 2.3303(5) Å respectively with respect  to the bond length for Ru-
Cl(3) of 2.4122(5) Å is attributed to the different trans influence of the pyridine nitrogen atom 
in comparison to the chloride atom. The pyrazole and pyridine rings are in the same plane, with 
dihedral angles of 79.49° and 79.36° respectively, in good agreement with those reported for 
similar ruthenium(III) complexes [13].  The average Ru-Npz, Ru-Npy and Ru-Cl bond lengths 
of 2.0639(15) Å, 1.9698(14) Å and 2.3655(5) Å in 3 compare well with the average bond 
distances of 2.086(2) Å, 1.988(2) Å  and 2.3531(6) Å,  respectively, for a recently reported  
2,6-bis-(3′,5′-diphenylpyrazolyl)pyridine ruthenium(III) complex [14]. 
 
Figure 1:  Molecular structure diagram of 3. Selected bond lengths (Å) and angles (°): Ru(1)-
N(1), 1.9698(14); Ru(1)-N(3), 2.0518(15); Ru(1)-N(5), 2.0760(15); Ru(1)-Cl(2), 2.3303(5); 
Ru(1)-Cl(1), 2.3540(5), Ru(1)-Cl(3), 2.4122(5); N(1)-Ru(1)-N(3), 79.49(6); N(3)-Ru(1)-N(5), 
158.85(6); N(3)-Ru(1)-Cl2(2), 88.08(5); N(5)-Ru(1)-Cl(2), 90.61(4); N(5)-Ru(1)-Cl(1), 
91.82(4); Cl(2)-Ru(1)-Cl(1), 174.906(16), N(3)-Ru(1)-Cl(3), 100.65(4); Cl(1)-Ru(1)-Cl(3), 
92.095(17). 
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The kinetics of ligand substitution reactions of complexes 1-3 with the biologically 
relevant thiourea (TU) was investigated. All the substitution reactions fitted into a single 
exponential decay, an indication that the three chloro atoms were substituted by thiourea 
simultaneously (Figure S2). Plots of kobs against the concentration of the incoming nucleophile 
gave straight line with zero intercept which means that the substitution reactions can be 
represented as shown in Figure 2, Scheme 2 and Equation 1. The values of the second order 
rate constant, k2, were obtained from the slopes of these plots (Figures S3) at 25 °C and are 
summarised in Table 2. Additional kinetics plots and data are given in supplementary Figures 
S3-S9 and Tables S2-S5. 
 
Figure 2: Concentration dependence of kobs for the substitution of chlorides from 1 (5.0 x 10
-4 
M) by TU (0.225 M) in methanol solution, I = 0.1 M (adjusted with NaClO4/LiCl) at 298 K. 
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Scheme 2: Proposed substitution mechanism for the mononuclear (pyrazolyl)pyridine 
ruthenium(III) complexes 1-3 with thiourea nucleophile. 
 
kobs = k2 [Nu]                                                                   (1) 
 
Table 2: Summary of the rate constants and activation parameters for the substitution of 
chloride ligand by TU nucleophile in complexes 1-3.a  
Complex Nu k2/M-1s-1×10-2 ΔH/kJmol-1 ΔS/Jmol-1K-1 
1   TU 5.00 ± 0.03 56 ± 1 -105 ± 3 
2 TU 2.25 ± 0.01 63 ± 1  -60 ± 3 
3 TU 0.24 ± 0.00 71 ± 1  -38 ± 3 
            aSolvent: methanol,  I = 0.1 M (adjusted with NaClO4/LiCl) at 298 K 
 
The temperature dependence studies were carried out using a temperature range of 25- 
45 °C in 5 °C intervals. The thermodynamic parameters, activation enthalpies, ΔH≠, and the 
activation entropies, ΔS≠, were calculated from the slopes and the intercepts of the Eyring plots 
(Figures 3, S4-S5 and Tables S5-S7) and are presented in Table 2. Computational modelling 
of the ruthenium(III) complexes was performed in order to provide insight to kinetics data. The 
geometry optimised structures and the frontier orbitals are given in Table S8 while a summary 
7 
 
of the respective HOMO-LUMO energies, chemical hardness, chemical potential, global 
electrophilicity index, NBO atomic charges and dipole moments are shown in Table 3.  
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Figure 3: Eyring plot obtained for the substitution of chloride from 1 by thiourea nucleophiles 
in methanolic solution, I = 0.1 M (0.01 M LiCl, 0.09 M NaClO4) at various temperatures in the 
range 25 - 45 °C. 
 
Table 3: Summary of the data obtained from the DFT calculations for complexes 1-3  
Parameter   1   2   3 
LUMO /eV -3.27 -2.66 -2.50 
HOMO /eV -6.90 -6.60 -6.49 
ΔE /eV 3.64 3.94 4.09 
η/eV 1.82 1.97 2.05 
μ/eV -5.08 -4.63 -4.44 
ω/eV 7.11 5.45 4.82 
Ru NBO charges 0.35 0.35 0.34 
Dipole moment (D) 20.52 19.52 17.49 
η = chemical hardness, μ = chemical potential and ω = global electrophilicity index. NBO = 
natural bond orbital. 
 
Comparing the rates of displacement of the coordinated chlorides by the thiourea 
nucleophile, the order of decreasing reactivity was found to be 1 > 2 > 3. The difference in 
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reactivity can be concluded to be due to electronic effects. This is supported by the DFT 
calculations which shows that the electrophilicity of the complexes are in line with the trend of 
the rates of the substitution reactions. To try and understand the observed reactivity trend, it is 
important to reflect on the properties of the spectator ligand. The pyridine ring readily accepts 
π-back bonding from the metal, while pyrazole rings are π-electron rich because of the extra 
pyrazolyl-N which make them better σ-donors [15-16]. This means that the pyrazole fragment 
has poor π-acceptor ability and good σ-donor ability. This property results in accumulation of 
electron density around the metal atom with a net reduction in the substitution of the chloro 
atom. In the present study, complex 1 is more reactive than 2 and 3 due to its higher 
electrophilicity compared to complexes 2 and 3, which contain an extra pyrazolyl motif.  
Secondly, the pyridine ring has an electron withdrawing bromide group [17] and 
thereby, enhancing the π-back bonding ability of the ring. Comparing complexes 2 and 3, the 
controlling factor is the presence of the pyrazolyl methyl substituents in 3. This enhances the 
σ-donor ability of the pyrazole ring while reducing its π-acceptor properties and thus makes 
the metal centre to be the least electropositive as supported by the DFT calculations and 
elecetrophilicity values (ω). In addition, the DFT calculations also support the role of the π-
back donation [18] through the values of dipole moments which shows a trend of 20.52 > 19.52 
> 17.49 for 1, 2 and 3 respectively. The overall substitution mechanism is associative in nature 
as supported by the large negative ΔS≠ values and relatively small ΔH≠ values. This means that 
the transition state is highly ordered accompanied with an easy bond formation [19]. 
The in vitro cytotoxicity of the investigated compounds against cultured HeLa cells was 
determined by assessing cell viability using the MTT assay, with the anti-cancer drug 
doxorubicin used as a positive control. Viability was assessed after incubating the cells with 
the compounds for 48 h. The effects on cell viability of the anti-cancer drug, doxorubicin, used 
as a positive control, as well as the effects of the ligands and their corresponding complexes 
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are shown in Figure 4, while representative images showing changes to cell morphology 
induced by the various concentrations of the compounds are given in Figure S6. Doxorubicin 
decreased cell viability in a concentration-dependent manner (*P<0.05, **P<0.01, 
***P<0.001), with an average IC50 of 0.8±0.2 µM (n=3). These deleterious effects of 
doxorubicin on cell viability are correlated, through brightfield microscopic examination, with 
progressive loss of cells and the rounding up of the remaining cells (Figure S6). The results 
show that the (pyrazolyl)pyridine ligands generally displayed relatively higher cytotoxic 
activities than  their respective ruthenium(III) metal complexes, as indicated by changes to 
viability (Figure 4) and morphology (Figure S6). For instance, L2, reduced viability 
concentration-dependently (IC50 of L2 = 83 µM) and, was significantly more cytotoxic than 
complex 2 (IC50 > 200 µM i.e no significant effect at concentrations tested). The difference 
could be due to the limited solubility of the complexes in DMSO [20], as we could not test the 
complexes beyond 100 µM while it was possible to test concentrations of the ligands up to 400 
µM. The minimal cytotoxicity of both the ligands and their complexes 1-3 as revealed by their 
relatively high IC50 values may be due to minimal aromaticity of the (pyrazolyl)pyridine 
ligands, which ultimately limits the interaction of the compounds with the DNA [20]. While 
there is no well documented relationship between ligand substitution reactions and anti-cancer 
activity, the favourable reactions of complexes 1-3 with TU may lead to cytoplasmic 
deactivation of the compounds before reaching the targeted DNA molecule [6]. Another factor 
that may account for the low activity of the compounds could be the resistant nature of the 
HeLa cell line compared to other cancer cell types [21].          
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Figure 4: Effects on the viability of HeLa cells of anti-cancer drug, doxorubicin (used as 
positive control), ligands L1-L3, and complexes 1-3. IC50 values are as indicated on the graphs. 
*P<0.05, **P<0.01 and ***P<0.001 compared to the negative control.  Values shown are Mean 
± SEM of 3-4 independent experiments.      
   
To examine the binding affinities and  sites of complexes 1-3 to DNA, molecular 
docking studies were carried out on complexes 1-3 with B-DNA (PDB ID: 1BNA). Docked 
images and relative binding energies of the investigated complexes are shown in Table S10. 
The docking results revealed that complexes 1-3 form stable complexes with DNA binding 
sites through non‐covalent interactions [22]. The negative binding energies suggest that the 
complexes interact in a parallel manner with respect to the minor/major grooves of the DNA 
backbone. The resulting relative binding energies of 1, 2, and 3 with the DNA were obtained 
as -209.05 kJ/mol, -232.00 kJ/mol and -251.58 kJ/mol, respectively (Table S10). Thus complex 
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3, shows better binding affinity to the DNA molecule, while complex 1 displays the least 
affinity.  The lower binding affinity of complex 1 may result from lack of planarity and its non-
symmetrical nature, in good agreement with DFT studies. The relative binding energies of the 
investigated complexes were inversely proportional to the rates of ligand substitution reactions.                                            
                                                        
In summary, we have successfully synthesised and structurally characterised 
ruthenium(III) complexes of (pyrazolyl)pyridine ligands. The rate of ligand substitution 
reactions in the complexes is controlled by the electrophilicity of the metal centre. The mode 
of activation was found to be associative and the relative DNA binding affinities of the 
compounds are controlled by the structure of the complexes. The investigated compounds 
showed minimal cytotoxicity towards Hela cells. Investigations are underway both to expand 
the scope of the cancer cell lines used to assess compound cytotoxicity in addition to 
modification of  the complex structures in order to improve the cell viability of the  compounds. 
 
Supplementary information 
Supplementary materials contains the synthetic, kinetic, and biological assay 
procedures. Spectroscopic data for the compounds, related Figures for the kinetics plots, 
optimized geometries and biological studies are contained in supplementary materials. 
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